Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01804686 · ClinicalTrials.gov registry record · Phase 3

A Long-term Extension Study of PCI-32765 (Ibrutinib)

A Phase 3 study of Chronic Lymphocytic Leukemia and Diffuse Large B Cell Lymphoma, sponsored by Janssen Research & Development.

Recruiting
Registry status
Phase 3
Development phase
700
Enrollment target
20
Study locations

NCT01804686: Recruiting Phase 3 study of Chronic Lymphocytic Leukemia and Diffuse Large B Cell Lymphoma, sponsored by Janssen Research & Development.

NCT01804686 is a Phase 3 study of Chronic Lymphocytic Leukemia and Diffuse Large B Cell Lymphoma that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 700 participants, above the 178-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (293% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01804686, a Phase 3 study of Chronic Lymphocytic Leukemia and Diffuse Large B Cell Lymphoma, is actively recruiting participants, sponsored by Janssen Research & Development.

RECRUITING
Registry status
Phase 3
Development phase
700 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.

Conditions Studied

Chronic Lymphocytic Leukemia Diffuse Large B Cell Lymphoma Mantle Cell Lymphoma Follicular Lymphoma Small Lymphocytic Lymphoma Waldenstrom Macroglobulinemia Chronic Graft Versus Host Disease

Interventions

  • DRUG Ibrutinib

Study Locations (20)

California

  • City of Hope Cancer Center - Duarte
  • University of California San Diego Medical Center - La Jolla
  • University of California Los Angeles - Los Angeles
  • St. Joseph Hospital Center for Cancer Prevention and Treatment - Orange
  • Stanford University Medical Center - Stanford
  • Stanford University - Stanford

Michigan

  • University of Michigan Comprehensive Cancer Center - Ann Arbor
  • Battle Creek Health Systm - Battle Creek
  • Karmanos Cancer Institute - Wayne State University - Detroit

Connecticut

  • Norwalk Medical Group - Norwalk

Georgia

  • Northwest Georgia Oncology Centers PC - Marietta

Illinois

  • Northwestern University Hospital - Chicago

Indiana

  • Indiana University - Goshen

Kansas

  • Kansas University Medical Center - Westwood

Kentucky

  • Louisville Oncology Suburban - Norton Cancer Institute - Louisville

Trial Details

FieldValue
Enrollment Target 700 participants
Start Date 2013-09-09
Est. Completion 2027-08-31
Phase Phase 3
Janssen Research & Development

593 total trials

What NCT01804686 shows while recruiting

NCT01804686 is an interventional study that assigns participants to a tested intervention. The registered 700 participants enrollment target is mid-sized for trials with a published cap, above the 178-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (293% higher).

The record links to 7 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Ibrutinib is the first listed.

NCT01804686 names 20 study sites across 13 states, led by California, Michigan, Connecticut.

Frequently Asked Questions

What is clinical trial NCT01804686 about?

NCT01804686 is a clinical study titled "A Long-term Extension Study of PCI-32765 (Ibrutinib)". The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively recei...

What is the current status of trial NCT01804686?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 700 participants. The study started on 2013-09-09. Estimated completion is 2027-08-31.

What conditions does trial NCT01804686 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma.

What interventions are being tested in trial NCT01804686?

The interventions under investigation include: Ibrutinib (DRUG).

Who is sponsoring clinical trial NCT01804686?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01804686 being conducted?

This trial has 20 study locations across California, Connecticut, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01804686's enrollment target sits among peer trials

700 9th of 187 higher than 179 of 187 other Chronic Lymphocytic Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00900419 · 700 participants

    Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers

  • NCT02107989 · 700 participants

    Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database

  • NCT02129543 · 700 participants

    Immune Reconstitution in Stem Cell Transplant Recipients

  • NCT02576483 · 700 participants

    An Evaluation of LASIK, SMILE and PRK Surgery in Physicians

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT01804686

Source: ClinicalTrials.gov NCT01804686, the US trial registry maintained by the National Library of Medicine. NCT01804686 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.